Myriad Genetics (MYGN) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Myriad Genetics (MYGN) over the last 9 years, with Q3 2025 value amounting to $0.32.
- Myriad Genetics' Debt to Equity rose 50139.59% to $0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 50139.59%. This contributed to the annual value of $0.06 for FY2024, which is 1490.19% up from last year.
- Myriad Genetics' Debt to Equity amounted to $0.32 in Q3 2025, which was up 50139.59% from $0.15 recorded in Q2 2025.
- Myriad Genetics' Debt to Equity's 5-year high stood at $0.32 during Q3 2025, with a 5-year trough of $0.05 in Q4 2023.
- In the last 4 years, Myriad Genetics' Debt to Equity had a median value of $0.06 in 2023 and averaged $0.09.
- In the last 5 years, Myriad Genetics' Debt to Equity surged by 331648.18% in 2021 and then plummeted by 538.81% in 2024.
- Over the past 4 years, Myriad Genetics' Debt to Equity (Quarter) stood at $0.12 in 2021, then tumbled by 57.38% to $0.05 in 2023, then grew by 14.9% to $0.06 in 2024, then surged by 467.51% to $0.32 in 2025.
- Its Debt to Equity was $0.32 in Q3 2025, compared to $0.15 in Q2 2025 and $0.08 in Q1 2025.